| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0001541 | Ovarian follicle development | Decreases phenotype | PMID:30733785 |
| GO:0001552 | Ovarian follicle atresia | Increases phenotype | PMID:30733785 |
| GO:0001556 | Oocyte maturation | Decreases phenotype | PMID:30733785 |
| GO:0001659 | Temperature homeostasis | Affects phenotype | PMID:25211138 |
| GO:0001678 | Cellular glucose homeostasis | Affects phenotype | PMID:21549692 |
| GO:0002024 | Diet induced thermogenesis | Increases phenotype | PMID:2307116 |
| GO:0002064 | Epithelial cell development | Affects phenotype | PMID:22223845 |
| GO:0002523 | Leukocyte migration involved in inflammatory response | Increases phenotype | PMID:21549692; PMID:34560825; PMID:38084638 |
| GO:0004035 | Alkaline phosphatase activity | Increases phenotype | PMID:34560825 |
| GO:0004069 | L-aspartate:2-oxoglutarate aminotransferase activity | Increases phenotype | PMID:18048028; PMID:34560825 |
| GO:0004095 | Carnitine o-palmitoyltransferase activity | Affects phenotype | PMID:15044358 |
| GO:0004111 | Creatine kinase activity | Increases phenotype | PMID:26900785; PMID:26900785; PMID:34560825 |
| GO:0004364 | Glutathione transferase activity | Affects phenotype | PMID:26319613; PMID:29441869 |
| GO:0004457 | Lactate dehydrogenase activity | Increases phenotype | PMID:26900785; PMID:26900785; PMID:34560825 |
| GO:0004602 | Glutathione peroxidase activity | Affects phenotype | PMID:25473020; PMID:26900785; PMID:29679905 |
| GO:0004784 | Superoxide dismutase activity | Affects phenotype | PMID:18048028; PMID:26900785; PMID:29679905; PMID:30733785; PMID:34560825; PMID:38084638 |
| GO:0005391 | P-type sodium:potassium-exchanging transporter activity | Decreases phenotype | PMID:21999347 |
| GO:0006006 | Glucose metabolic process | Increases phenotype | PMID:38084638 |
| GO:0006094 | Gluconeogenesis | Affects phenotype | PMID:11319642; PMID:18048028; PMID:28708105 |
| GO:0006114 | Glycerol biosynthetic process | Affects phenotype | PMID:11319642 |
| GO:0006325 | Chromatin organization | Increases phenotype | PMID:15139026 |
| GO:0006695 | Cholesterol biosynthetic process | Affects phenotype | PMID:18048028; PMID:18048028; PMID:21549692; PMID:19724016; PMID:19724016; PMID:22223845; PMID:22415589; PMID:29679905; PMID:32103741; PMID:19800637; PMID:21549692; PMID:21999347; PMID:22223845; PMID:22415589; PMID:23783067; PMID:25834641; PMID:26092479; PMID:29679905; PMID:32103741 |
| GO:0006749 | Glutathione metabolic process | Affects phenotype | PMID:38084638 |
| GO:0006750 | Glutathione biosynthetic process | Decreases phenotype | PMID:22447225; PMID:26900785 |
| GO:0006809 | Nitric oxide biosynthetic process | Increases phenotype | PMID:21999347 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:22169520; PMID:36732937 |
| GO:0006954 | Inflammatory response | Increases phenotype | PMID:26670228; PMID:32103741 |
| GO:0007033 | Vacuole organization | Increases phenotype | PMID:15139026; PMID:38084638 |
| GO:0007283 | Spermatogenesis | Increases phenotype | PMID:24502529 |
| GO:0007285 | Primary spermatocyte growth | Affects phenotype | PMID:24502529 |
| GO:0007409 | Axonogenesis | Increases phenotype | PMID:30837834 |
| GO:0007631 | Feeding behavior | Decreases phenotype | PMID:12077204; PMID:25473020; PMID:25497710 |
| GO:0008219 | Cell death | Affects phenotype | PMID:12077204; PMID:15044358; PMID:20376352; PMID:29328403; PMID:19093718; PMID:19151514; PMID:19733649; PMID:2004597; PMID:20376352; PMID:29328403; PMID:30837834; PMID:3299706 |
| GO:0008283 | Cell population proliferation | Increases phenotype | PMID:24502529; PMID:25497710 |
| GO:0008361 | Regulation of cell size | Affects phenotype | PMID:15139026 |
| GO:0008610 | Lipid biosynthetic process | Increases phenotype | PMID:11319642; PMID:26670228; PMID:34560825 |
| GO:0009062 | Fatty acid catabolic process | Affects phenotype | PMID:11319642; PMID:18048028 |
| GO:0014009 | Glial cell proliferation | Increases phenotype | PMID:20928830 |
| GO:0015020 | Glucuronosyltransferase activity | Affects phenotype | PMID:25663641 |
| GO:0015734 | Taurine transport | Decreases phenotype | PMID:31569818 |
| GO:0016042 | Lipid catabolic process | Increases phenotype | PMID:21549692; PMID:21999347; PMID:22447225; PMID:26900785; PMID:29679905 |
| GO:0016887 | Atp hydrolysis activity | Decreases phenotype | PMID:21999347 |
| GO:0018158 | Protein oxidation | Increases phenotype | PMID:29679905 |
| GO:0019432 | Triglyceride biosynthetic process | Increases phenotype | PMID:11319642; PMID:18048028; PMID:18048028; PMID:19724016; PMID:21549692; PMID:18048028; PMID:19800637; PMID:21549692; PMID:28708105; PMID:19001666; PMID:19724016; PMID:20111022; PMID:22223845; PMID:22415589; PMID:29679905; PMID:19724016; PMID:19800637; PMID:20111022; PMID:21549692; PMID:21999347; PMID:22223845; PMID:22415589; PMID:23783067; PMID:25211138; PMID:26092479; PMID:26092479; PMID:26670228; PMID:28708105; PMID:29679905 |
| GO:0030263 | Apoptotic chromosome condensation | Affects phenotype | PMID:28954212; PMID:38084638 |
| GO:0030391 | Fructosamine biosynthetic process | Increases phenotype | PMID:28708105 |
| GO:0030431 | Sleep | Increases phenotype | PMID:25697375 |
| GO:0032098 | Regulation of appetite | Affects phenotype | PMID:19093718 |
| GO:0034440 | Lipid oxidation | Increases phenotype | PMID:38084638 |
| GO:0035812 | Renal sodium excretion | Increases phenotype | PMID:31569818 |
| GO:0035930 | Corticosteroid hormone secretion | Increases phenotype | PMID:31077719 |
| GO:0035934 | Corticosterone secretion | Increases phenotype | PMID:8071649 |
| GO:0035936 | Testosterone secretion | Decreases phenotype | PMID:14657608; PMID:24502529 |
| GO:0035937 | Estrogen secretion | Decreases phenotype | PMID:30733785 |
| GO:0035941 | Androstenedione secretion | Decreases phenotype | PMID:14657608 |
| GO:0036359 | Renal potassium excretion | Increases phenotype | PMID:31569818 |
| GO:0042632 | Cholesterol homeostasis | Decreases phenotype | PMID:31981724 |
| GO:0042701 | Progesterone secretion | Decreases phenotype | PMID:14657608 |
| GO:0043005 | Neuron projection | Decreases phenotype | PMID:39581299 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:28954212; PMID:34560825; PMID:36732937; PMID:39581299 |
| GO:0045852 | Ph elevation | Increases phenotype | PMID:31569818 |
| GO:0048143 | Astrocyte activation | Increases phenotype | PMID:20928830 |
| GO:0048874 | Host-mediated regulation of intestinal microbiota composition | Affects phenotype | PMID:32103741 |
| GO:0051092 | Positive regulation of nf-kappab transcription factor activity | Increases phenotype | PMID:22169520 |
| GO:0051790 | Short-chain fatty acid biosynthetic process | Affects phenotype | PMID:32103741 |
| GO:0051939 | Gamma-aminobutyric acid import | Decreases phenotype | PMID:19733649 |
| GO:0060612 | Adipose tissue development | Increases phenotype | PMID:15809509; PMID:18048028; PMID:19093718; PMID:19093718; PMID:19724016; PMID:20111022; PMID:20111022; PMID:21549692; PMID:21549692; PMID:25497710; PMID:3299706 |
| GO:0060613 | Fat pad development | Increases phenotype | PMID:22415589; PMID:26092479 |
| GO:0061900 | Glial cell activation | Increases phenotype | PMID:30837834 |
| GO:0070265 | Necrotic cell death | Increases phenotype | PMID:34560825; PMID:38084638 |
| GO:0070342 | Brown fat cell proliferation | Decreases phenotype | PMID:25211138 |
| GO:0070343 | White fat cell proliferation | Increases phenotype | PMID:25211138; PMID:29328403 |
| GO:0070994 | Detection of oxidative stress | Affects phenotype | PMID:34560825 |
| GO:0070997 | Neuron death | Increases phenotype | PMID:12193538; PMID:15139026; PMID:9053782 |
| GO:0072520 | Seminiferous tubule development | Affects phenotype | PMID:24502529 |
| GO:0140042 | Lipid droplet formation | Increases phenotype | PMID:19001666; PMID:19724016; PMID:25211138 |
| GO:1903409 | Reactive oxygen species biosynthetic process | Increases phenotype | PMID:29679905 |
| GO:1905517 | Macrophage migration | Increases phenotype | PMID:19800637; PMID:32103741 |
| GO:2000253 | Positive regulation of feeding behavior | Increases phenotype | PMID:12193538 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.